Buy Columvi in India — Price & Availability

What is Columvi used for?

Columvi (glofitamab-gxbm) is a bispecific antibody that binds CD20 on B-lymphoma cells and CD3 on T cells at the same time, bringing the patient’s own T cells into contact with the lymphoma cells so the T cells can destroy them.

It is approved for adults with:

• Relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.

This indication was granted under accelerated approval based on response rate and response durability. Columvi is given as a fixed-duration treatment. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist or haematologist.

Recommended dosage:
Columvi is given as an intravenous infusion on a step-up dosing schedule in 21-day cycles to reduce the risk of cytokine release syndrome (CRS):

• A single dose of obinutuzumab is given 7 days before the first
• Columvi dose to deplete circulating B cells.
  Columvi is then started with step-up doses (a smaller dose followed by increasing doses) before reaching the full target dose, continuing for a fixed number of cycles.
• Premedication is given before each dose, and patients are hospitalised during and for 24 hours after the first step-up dose for monitoring.

The treating doctor determines the exact schedule and the number of cycles. Columvi must be given only as an IV infusion.

Boxed warning — cytokine release syndrome (CRS): CRS, including serious or fatal reactions, can occur with Columvi. Premedication and the step-up dosing schedule are used to reduce the risk, and treatment is withheld until CRS resolves or permanently discontinued based on severity.

• Neurologic toxicity (including ICANS): Treatment may affect the nervous system. Contact your doctor immediately if you experience confusion, difficulty speaking, tremors, seizures, memory problems, or any new or worsening neurological symptoms.
• Serious infections: Serious infections, including life-threatening infections, may occur during treatment. Your doctor will monitor you closely, especially if you are older or develop symptoms such as fever or persistent cough.
• Tumour flare: Some patients may experience tumour flare, causing temporary swelling, pain, or worsening symptoms. Inform your doctor promptly if you notice any new or worsening discomfort during treatment.
• Immunisations: Do not receive live vaccines while undergoing treatment unless your doctor advises otherwise, as your immune system may not respond normally and the risk of infection may increase.
• Embryo-fetal toxicity and breastfeeding: This medicine may harm an unborn baby. Use effective contraception during treatment, and do not breastfeed while receiving therapy or for one month after the final dose.

Common side effects:
Common side effects include cytokine release syndrome, along with musculoskeletal pain, rash, fatigue, and low blood counts. This is not a complete list — refer to the full prescribing information and your treating doctor.

Patients in India can legally access Columvi through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
  Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Columvi is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.

Documents required to import Columvi

• A valid prescription from a qualified oncologist or haematologist
• The patient’s diagnostic reports
• Government-issued patient ID proof
• An import permit, where applicable

Because Columvi is not sold on the open market in India, there is no fixed MRP. The Columvi cost in India depends on a few factors at the time of import:

• The number of vials required across the step-up dosing schedule and subsequent cycles, plus the obinutuzumab pre-treatment dose given before the first Columvi dose.
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Columvi cost, logistics, and delivery timeline once a valid prescription is shared. Request your Columvi quote →

Columvi is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid prescription, in line with applicable regulations.

Indian Pharma Network sources Columvi from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Columvi vials require cold-chain handling: stored refrigerated at 2 °C–8 °C in the original carton, protected from light, and not frozen or shaken. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Is Columvi available in India?

Columvi (glofitamab-gxbm injections) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of the current publicly available information, Columvi is not commercially marketed in India.

However, patients in India can legally access Columvi through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Columvi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
  Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Columvi price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
• Ensuring full transparency throughout the process

Columvi can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:
Columvi received US FDA accelerated approval on 15 June 2023 for relapsed or refractory DLBCL (not otherwise specified) or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy. It is also approved in the European Union and other markets. As of the current publicly available information, Columvi is not commercially marketed in India, which is why the Named Patient route is used.